GUANGZHOU, China, May 20 /PRNewswire-Asia/ -- China Medicine Corporation (OTC Bulletin Board: CHME) (“China Medicine” or “the Company”), a developer and leading distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (“TCM”), nutritional and dietary-supplements, medical devices, and medical formulations in the People’s Republic of China (“PRC”), announced that it held its Annual Meeting of Shareholders (the “AMS”) on May 19th, 2009, in New York City.
At the meeting, a proposal to change the Company’s domicile from Delaware to Nevada pursuant to a plan of merger, as set out in the Company’s proxy statement, was approved by a majority of shares outstanding and entitled to vote. In addition, a proposal for the election of five directors to serve until the AMS in 2010 was also approved by a majority of shares present at the meeting, by proxy or in person, and entitled to vote. Specifically, shareholders elected Mr. Senshan Yang, Ms. Minhua Liu, Mr. Robert Adler, Ms. Rachel Gong, and Mr. Yanfang Chen as members of the Board of Directors of the Company.
About China Medicine Corporation
China Medicine Corporation is a developer and leading distributor of prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. China Medicine also has its research and development force for certain products it manufactures through OEM arrangement and distributes. The Company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company’s website at http://www.chinamedicinecorp.com .
Company Contact:
Ms. Huizhen Yu
Chief Financial Officer
China Medicine Corp
Tel: +86-20-8739-1718
Email: konzern08@163.com
Investor Relations Contact:
Mr. Crocker Coulson, President
CCG Investor Relations
Tel: +1-646-213-1915 (NY Office)
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
